Advances in Adult-Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis

Dear Colleagues,

Adult-onset Still’s disease and systemic juvenile idiopathic arthritis are rare auto-inflammatory disorders with unknown etiology and complex pathophysiology. The many common features support the recognition of these being one disease with different ages of onset.

The pathogenesis of Still’s disease involves a genetic background, environmental triggers, and autoinflammatory immune response, with main participation of innate immunity (i.e. neutrophils and macrophages as well as pro-inflammatory cytokines. Interleukin (IL)-1 pathway has been reported as the major defective pathway in Still’s disease. The diagnosis of Still’s disease remains challenging and specific biomarkers are lacking. The prognosis is also difficult to establish a priori, therefore, there is an urgent need to identify better biomarkers.

In recent years, biotherapies have been gradually but surely imposed as alternatives to corticosteroids, very early on in the therapeutic strategy. “Window of opportunity” and “treat to target” are two concepts whose relevance in the management of AOSD is currently highlighted. In addition, new molecules, such as JAK inhibitors or anti-interferon gamma, are being evaluated in these contexts.

The Special Issue entitled “Advances in adult-onset Still’s disease and systemic juvenile idiopathic arthritis” of the Journal of Clinical Medicine is now open for submissions. This issue welcomes all types of papers* on the broad spectrum of epidemiology, pathophysiology (including genetics and basic science), clinical characteristics, evaluation of the classification criteria, prognosis (biomarkers), comparison of both diseases, complications, and management. This special issue aims to provide the reader with a comprehensive overview of current knowledge, as well as a description of the remaining challenges and future avenues to overcome them.

*Guest editors will not accept case reports. Some case reports accompanied by high-level literature review (case-based reviews) will be considered. Viewpoints from recognized experts are welcome. 

Dr. Jamilloux Yvan
Dr. Mathieu Gerfaud-Valentin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.